Who owns Trajan Group Holdings Limited?
The Tomisich family retains significant influence after founding Trajan in 2011 and leading its 2021 ASX listing that raised 90 million AUD. Institutional investors and retail shareholders now share ownership, shaping governance and strategic priorities.
Major shareholders include the founding Tomisich family, Perennial Value Management and Regal Funds Management, with remaining free float among institutional and retail investors; voting power and board alignment determine control.
See product analysis: Trajan Porter's Five Forces Analysis
Who Founded Trajan?
Founders and Early Ownership of Trajan Group Holdings were concentrated within the Tomisich family, enabling a disciplined buy-and-build strategy led by the founders with no early venture dilution.
Co-founded in 2011 by Stephen Tomisich (CEO) and Angela Tomisich; leadership originated from prior industry roles.
Equity held 100 percent by Tomisich Family Pty Ltd and related private vehicles at inception, preserving control.
Early growth financed by internal cash flow and debt facilities; no angel or VC dilution in the first decade.
2013 acquisition of Grale Scientific's chromatography business and 2016 purchase of Leap Technologies expanded capabilities.
Founders retained absolute control over intellectual property and acquisition strategy during early growth.
By the 2021 IPO, founders still held the vast majority of equity, enabling favorable leverage in valuation negotiations.
The concentrated ownership model—documented in company filings and investor materials—meant no documented ownership disputes and a stable leadership team through 2020, until capital needs for global expansion prompted the structured sell-down at IPO.
Founding and ownership details relevant to Trajan Company ownership and Trajan Group structure.
- Founder and CEO: Stephen Tomisich; co-founder: Angela Tomisich.
- Initial legal owner: Tomisich Family Pty Ltd held 100 percent at inception in 2011.
- Early funding: internal cash flow and debt; no venture capital rounds in first decade.
- Major early acquisitions: chromatography business from Grale Scientific (2013) and Leap Technologies (2016).
For more on the company's origins and evolution, see Brief History of Trajan
How Has Trajan’s Ownership Changed Over Time?
Key events shaping Trajan Company ownership include the 18 June 2021 ASX listing (ticker TRJ) which raised 50 million AUD and a founders’ secondary sell-down of 40 million AUD, subsequent capital raises and incentive schemes, and the 2022 CRS acquisition that shifted shareholder focus to global expansion.
| Event | Date | Impact on Ownership |
|---|---|---|
| ASX IPO (new shares + secondary sell-down) | 18 Jun 2021 | Raised 50M AUD; founders sold 40M AUD; Tomisich family retained controlling stake |
| Acquisition of Chromatography Research Supplies (CRS) | 2022 | Funded and endorsed by institutional investors; expanded North American footprint |
| Executive incentive schemes & capital raises | 2022–2024 | Minor dilution of founder stake; governance tightened |
The current ownership structure of Trajan Company reflects a mix of dominant founder control and meaningful institutional participation: Tomisich Family Pty Ltd holds 75,564,258 shares (~50.22% voting power) as of late 2024, institutional holders provide liquidity and oversight, and the free float is ~40%.
Founder-led control remains strong while institutions back growth and acquisitions, balancing strategic vision with capital and governance.
- Tomisich Family Pty Ltd — largest shareholder (~50.22%)
- Perennial Value Management — ~8.9% stake
- Regal Funds Management and Dawsons — historically between 3–6% each
- Public/free float — approximately 40%, enabling retail and smaller professional investor participation
Institutional interest is driven by Trajan’s defensive life-sciences positioning and revenue growth to 162.2M AUD in FY2024; major shareholders monitor debt metrics and integration outcomes as the company pursues further global expansion — see Mission, Vision & Core Values of Trajan for related corporate context.
Who Sits on Trajan’s Board?
The Trajan Company board combines founder leadership with a majority of independent directors to balance control and governance: Sara Watts serves as Independent Non-Executive Chair, with Stephen Tomisich as CEO and Managing Director, supported by Independent Non-Executive Directors John Langdon and Robert Lyon.
| Director | Role | Key Focus |
|---|---|---|
| Sara Watts | Independent Non-Executive Chair | Audit and risk oversight |
| Stephen Tomisich | Chief Executive Officer & Managing Director | Operational leadership; founder representation |
| John Langdon | Independent Non-Executive Director | Commercial strategy and human resources |
| Robert Lyon | Independent Non-Executive Director | Legal, compliance and governance frameworks |
Trajan Group Holdings follows a one-share-one-vote structure; the Tomisich family holds a controlling 50.22 percent stake, enabling effective majority control while the board’s independent majority and formal committees mitigate risks to minority shareholders and align with ASX Corporate Governance Council recommendations.
The board’s independent majority is designed to provide objective oversight despite concentrated founder voting power.
- The Tomisich family owns 50.22 percent, giving them decisive influence on ordinary resolutions.
- One-share-one-vote structure; no dual-class or golden shares exist.
- Audit & Risk and Remuneration & Nomination Committees oversee financial reporting and executive pay.
- No major proxy fights or activist campaigns recorded through 2025; transparency on M&A and financial guidance credited.
For context on strategic positioning and investor targeting, see Target Market of Trajan.
What Recent Changes Have Shaped Trajan’s Ownership Landscape?
From 2023 to 2025 Trajan Company ownership has shifted from rapid expansion to consolidation, with management prioritizing debt reduction and stabilizing the shareholder register; institutional holders have shown increased 'sticky' ownership while LTIP vesting produced minor executive share increases.
| Metric | FY24 / 2024 | Trend |
|---|---|---|
| Net debt | 34.5 million AUD | Reduced from prior highs |
| EBITDA | 28.5 million AUD | Supports operations without major secondary raises |
| Ownership mix | Higher institutional 'sticky' holdings; minor insider LTIP dilution | Stabilizing; retention-focused |
Institutional investors have largely retained positions despite small-cap life sciences volatility, while LTIP-related vesting slightly increased internal ownership; no major secondary offerings occurred in 2024–2025 as cashflow covered funding needs.
Management reduced net debt to 34.5 million AUD by FY24, improving leverage metrics and investor confidence in the Trajan Group structure.
Institutional holders increased average holding durations, creating a more 'sticky' investor base for Trajan Company ownership and reducing trading volatility.
Vesting of performance rights under the LTIP caused modest dilution but aligned senior management interests to EPS targets and shareholder value creation.
Enhanced reporting on sustainable manufacturing and ethical supply chains is broadening appeal to European and North American institutional capital focused on ESG.
Analysts expect potential succession planning as the business matures; CEO Stephen Tomisich remains engaged while the company reiterates its intent to stay publicly listed and avoid privatization; see Growth Strategy of Trajan for related context.
- What is Brief History of Trajan Company?
- What is Competitive Landscape of Trajan Company?
- What is Growth Strategy and Future Prospects of Trajan Company?
- How Does Trajan Company Work?
- What is Sales and Marketing Strategy of Trajan Company?
- What are Mission Vision & Core Values of Trajan Company?
- What is Customer Demographics and Target Market of Trajan Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.